Braveheart Bio (BRVE) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Braveheart Bio is the larger company by market cap ($1.67 billion vs $1.56 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | STOK |
|---|---|---|
| Share price | $18.55 | $24.17 |
| Market cap | $1.67B | $1.56B |
| 1-day change | -0.16% | -0.49% |
| YTD return | — | -23.47% |
| 1-year return | — | -11.06% |
| 5-year return | — | +3.27% |
| EPS (TTM) | $-6.08 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $32.00 | $40.22 |
| 52-week low | $17.86 | $20.32 |
| Distance from 52-week high | -42.03% | -39.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +143.94% | +92.22% |
| Average volume | 562.23K | 852.03K |
| Shares outstanding | 90.04M | 64.53M |
| Employees | 49 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
BRVE vs STOK FAQ
Which is bigger, Braveheart Bio or Stoke Therapeutics?
Braveheart Bio (BRVE) is larger, with a market capitalization of $1.67B compared with $1.56B for Stoke Therapeutics (STOK).
Are Braveheart Bio and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.